Enanta Pharmaceuticals (ENTA) Net Cash Flow (QoQ) (2012 - 2026)
Enanta Pharmaceuticals (ENTA) Net Cash Flow (QoQ) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Enanta Pharmaceuticals | 376.07 Mn | 212.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -148.82% |
| Dec 31, 2025 | 141.07% |
| Sep 30, 2025 | 18.75% |
| Jun 30, 2025 | 37.76% |
| Mar 31, 2025 | -152.52% |
| Dec 31, 2024 | 3,131.55% |
| Sep 30, 2024 | 105.25% |
| Jun 30, 2024 | -217.61% |
| Mar 31, 2024 | 151.94% |
| Dec 31, 2023 | -364.35% |
| Sep 30, 2023 | -144.50% |
| Jun 30, 2023 | -28.93% |
| Mar 31, 2023 | 1,847.88% |
| Dec 31, 2022 | -111.33% |
| Sep 30, 2022 | 268.72% |
| Jun 30, 2022 | 84.05% |
| Mar 31, 2022 | -238.74% |
| Dec 31, 2021 | -20.42% |
| Sep 30, 2021 | 172.53% |
| Jun 30, 2021 | -429.20% |